Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

PBLA - Panbela Therapeutics Inc. Stock Price, Fair Value and News

$0.39+0.07 (+21.88%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

PBLA Price Action

Last 7 days

-5.4%

Last 90 days

9.4%

Trailing 12 Months

-49.3%

PBLA RSI Chart

JunJulAugSepOctNovDec2025FebMar102030405060708090

PBLA Valuation

Market Cap

1.9M

Price/Earnings (Trailing)

-0.07

Price/Sales (Trailing)

1.5K

EV/EBITDA

-0.18

Price/Free Cashflow

-0.12

PBLA Price/Sales (Trailing)

2022202320240100K200K300K400K500K600K

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PBLA Fundamentals

PBLA Revenue

Revenue (TTM)

1.0K

20122013201420152016201720180200K400K600K800K1M1.2M

PBLA Earnings

Earnings (TTM)

-27.9M

Earnings Growth (Yr)

8.42%

Earnings Growth (Qtr)

-0.36%

2012201420162018202020222024-40M-30M-20M-10M0

PBLA Profitability

Operating Margin

-48652.00%

EBT Margin

-2806850.00%

Return on Equity

153.37%

Return on Assets

-540.11%

Free Cashflow Yield

-822.87%

PBLA Investor Care

Shares Dilution (1Y)

1793.58%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
2012201320142015201620170200K400K600K800K1M1.2M
Net sales
YearQ1Q2Q3Q4
20180000
201703.0K2.0K1.0K
20167.0K5.0K5.0K4.0K
20150008.0K
20140000
20131.2M1.1M1.0M973.8K
20120001.2M
2011000699.8K
Get all data in R, Python etc through our Historical Stock Data APIs

About Panbela Therapeutics Inc.

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with cancer. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin (SBP-101). The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
 CEO
 WEBSITEpanbela.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES6

Panbela Therapeutics Inc. Frequently Asked Questions

What is the ticker symbol for Panbela Therapeutics Inc.? What does PBLA stand for in stocks?

PBLA is the stock ticker symbol of Panbela Therapeutics Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Panbela Therapeutics Inc. (PBLA)?

As of Tue Mar 11 2025, market cap of Panbela Therapeutics Inc. is 1.89 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PBLA stock?

You can check PBLA's fair value in chart for subscribers.

Is Panbela Therapeutics Inc. a good stock to buy?

The fair value guage provides a quick view whether PBLA is over valued or under valued. Whether Panbela Therapeutics Inc. is cheap or expensive depends on the assumptions which impact Panbela Therapeutics Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PBLA.

What is Panbela Therapeutics Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Mar 11 2025, PBLA's PE ratio (Price to Earnings) is -0.07 and Price to Sales (PS) ratio is 1.46 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PBLA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Panbela Therapeutics Inc.'s stock?

In the past 10 years, Panbela Therapeutics Inc. has provided -0.726 (multiply by 100 for percentage) rate of return.